CRISPR-Cas9-based target validation for p53-reactivating model compounds von Wanzel, M, Vischedyk, J, Gittler, M, Gremke, N, Mernberger, M, Charles, J, Schneikert, J, Bretz, A.C, Nist, A, Stiewe, T

Volltext

PO-233 Chemoresistant NSCLC cells are hypersensitive to metabolic drugs due to mTOR-mediated inhibition of autophagy von Wanzel, M, Gremke, N, Schmoll, L, Pagenstecher, A, Schneikert, J, Stiewe, T

Volltext

EPH134 Prevalence of and Associated Factors for Therapy Delay Due to COVID-19 Pandemic Among Breast Cancer Patients in Europe von Gremke, N., Alymova, S., Kostev, K., Kalder, M., Klein, I.

Volltext

562 - CRISPR-Cas9-based target validation for p53-reactivating model compounds von Wanzel, M., Vischedyk, J., Gittler, M., Gremke, N., Mernberger, M., Charles, J., Schneikert, J., Bretz, A.C., Nist, A., Stiewe, T.

Volltext

Developmentally Regulated mRNAs in Mouse Liver von Barth, Richard K., Gross, Kenneth W., Gremke, Linda C., Hastie, Nicholas D.

Volltext